All In Biotech

Drug Trial Radar · NCT02859961

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 562 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

562

Actual

Start

Dec 7, 2016

Primary completion

Sep 16, 2020

Study completion Dec 7, 2020

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
First posted
Aug 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry. Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.

Conditions

  • HIV

Interventions

  • PRO 140 (350 mg)Drug

    PRO 140 350 mg (175 mg/mL) SC injection per week

  • PRO 140 (525 mg)Drug

    PRO 140 525 mg (175 mg/mL) SC injection per week

  • PRO 140 (700 mg)Drug

    PRO 140 700 mg (175 mg/mL) SC injection per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic FailureTime frame: From T1 (first treatment administration) to week 48 (T48).

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • CD03 Investigational site

    La Mesa, California

  • CD03 Investigational site

    Palm Springs, California

  • CD03 Investigational site

    San Francisco, California

  • CD03 Investigational site

    New Haven, Connecticut

  • CD03 Investigational site

    Norwalk, Connecticut

  • CD03 Investigational site

    Ft. Pierce, Florida

  • CD03 Investigational site

    Orlando, Florida

  • CD03 Investigational site

    West Palm Beach, Florida

  • CD03 Investigational site

    Wichita, Kansas

  • CD03 Investigational site

    Las Vegas, Nevada

  • CD03 Investigational site

    New York, New York

  • CD03 Investigational site

    Syracuse, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.